Storyline highlights The digital system is intended to treat schizophrenia, bipolar We disorder and depression in adults
The medication without sensor technology was approved to treat schizophrenia in 2002
(CNN) A psychiatric medication system in the form of a pill with an integral digital tracking unit gained acceptance from the US Food and Medicine Administration on Monday.
Abilify MyCite, a form of aripiprazole and a first-of-its-kind product, has an embedded ingestible sensor that records when the medication is considered. Made by Japan-structured Otsuka Pharmaceutical Co., the medication system is intended to treat schizophrenia, bipolar I disorder and unhappiness in people. Abilify without sensor technology was initially approved to treat schizophrenia in 2002.
Schizophrenia, a psychotic disorder, includes symptoms of delusions and hallucinations. Bipolar patients may knowledge alternating episodes of mania and unhappiness, a persistent sadness.
Though the idea behind Abilify MyCite is to boost a patient’s compliance with their medication regimen, the FDA noted that is not proved.
Teens and young adults who are acquiring antidepressants are at increased threat of suicidal tendencies and thoughts when acquiring the medication, cautions a boxed warning ; they should be monitored closely. Security and effectiveness is not established in children. Abilify MyCite is also not approved to treat older patients with dementia-related psychosis.